Studies of 99mTc-BnAO (HL-91): A non-nitroaromatic compound for hypoxic cell detection

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 4, 1998, Pages 737-740

  Zhang, X ^a,b   Melo, T ^b   Ballinger, J R ^a,c   Rauth, A M ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

99mBnAO; Diagnostic; HL 91; Hypoxia; Solid tumours

Indexed keywords

2,2' (1,4 DIAMINOBUTANE)BIS(2 METHYL 3 BUTANONE)DIOXIME TECHNETIUM TC 99M; OXIME DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; TECHNETIUM 99M; TUMOR MARKER; UNCLASSIFIED DRUG; UPENAZIME; UPENAZIME TC 99M; OXIME; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CHO CELL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG HALF LIFE; HYPOXIC CELL; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RADIOACTIVITY; SOLID TUMOR; TISSUE OXYGENATION; ANIMAL; ARTICLE; C3H MOUSE; CELL HYPOXIA; EXPERIMENTAL NEOPLASM; HAMSTER; METABOLISM; TISSUE DISTRIBUTION;

ANIMALS; CELL HYPOXIA; CHO CELLS; CRICETINAE; MICE; MICE, INBRED C3H; NEOPLASMS, EXPERIMENTAL; ORGANOTECHNETIUM COMPOUNDS; OXIMES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 0031597439     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00301-0     Document Type: Conference Paper

References (17)

1. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond.). 379:1996;88-91.
2. Brizel D.M., Scully S.P., Harrelson J.M., Lagfield L.J., Bean J.M., Posnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
3. Höckel M., Schlenger K., Mitze M., Schäffer U., Vaupel P. Hypoxia and radiation response in human tumours. Semin Radiol Oncol. 6:1996;3-9.
4. Nunn A., Linder K., Strauss H.W. Nitromidazoles and imaging hypoxia. Eur J Nucl Med. 22:1995;265-280.
5. Cook G.J.R., Barrington S., Houston S., Maisey M.N., Fogelman I. HL91, a new Tc-99m-labelled agent with potential for identifying tumour hypoxia correlation with FDG PET . J Nucl Med. 37:1996;87P-88P.
6. Thorne N. 2-Methylbut-2-ene nitrosochloride and its derivatives. Chemical Society Journal (London). 1956;2587-2589.
7. Vassian E.G., Murmann R.K. Aromatization of an aliphatic oxime nickel (II) complex by molecular oxygen. Inorganic Chem. 6:1967;2043-2046.
8. Ballinger J.R., Gulenchyn K.Y. Alternative formulations of technetium 99m HMPAO. Appl Radiat Isot. 42:1991;315-316.
9. Brauers G., Archer C.M., Burke J.F. The chemical characterization of the tumour imaging agent 99mTc-HL91. Eur J Nucl Med. 24:1997;943.
10. Ballinger J.R., Kee J.W.M., Rauth A.M. In vitro and in vivo evaluation of a technetium-99m-labelled 2-nitromidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med. 37:1996;1023-1031.
11. Cowan D.S.M., Hicks K.O., Wilson W.R. Multi-cellular membranes as an in vitro model for extravascular diffusion in tumours. Br J Cancer. 74:(Suppl. 27):1996;S28-S31.
12. 3H] misonidazole binding and paired survival assay . Radiat Res. 145:1996;491-500.
13. Whillans D.W., Rauth A.M. An experimental and analytical study of oxygen depletion in stirred cell suspensions. Radiat Res. 84:1980;97-114.
14. Wood P.J., Stratford I.J., Adams G.E., Szabo C., Thiemermann C., Vane J.R. Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem Biophys Res Commun. 192:1993;505-510.
15. Melo T., Hua H.A., Ballinger J.R., Rauth A.M. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics. Biochem Pharmacol. 54:1997;685-693.
16. Okada R.D., Johnson G. III, Nguyen K.N., Edwards B., Archer C.M., Kelly J.D. Effects of low flow and hypoxia on a new ischemia-avid myocardial imaging agent. Circulation. 95:1997;1892-1899.
17. Cook G.J.R., Houston S., Barrington S.F., Fogelman I. Technetium-99m-labelled HL91 to identify tumour hypoxia correlation with fluorine-18-FDG . J Nucl Med. 39:1998;99-103.